Key Drivers
- Strong Margins
- Cash Flow Power
- Liquidity Slip
AIAI Summary
NBIX is evolving from a one-product story into a multi-engine growth platform, but with INGREZZA still carrying results, CRENESSITY/VYKAT XR still being proven, and valuation already demanding flawless execution, the stock remains a “show me” name where safety, adoption, and reinvestment discipline will determine whether the diversification story translates into upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Cash Flow Power
- •Liquidity Slip
NBIX remains fundamentally strong with high margins and robust free cash flow, but softer quarter-end liquidity, heavier intangibles, and a premium valuation temper upside.
Price Behavior
Key Price Behavior Insights:
- •Trend reversal
- •Support holding
- •Lower highs
NBIX has flipped from an uptrend into a fragile downtrend over the last month, with $150-$153 as short-term support and a move back above the mid-$160s needed to confirm a reversal.
Sharp drop from about $185.50 into the $150s after 2026-07-31 reversed momentum quickly
Sentiment & News
Key News Insights:
- •Sales Growth
- •Pipeline Progress
- •Safety Concerns
Neurocrine posted strong Q2 results and raised INGREZZA guidance, while pipeline progress, leadership changes, and VYKAT XR safety concerns created a mixed but generally constructive outlook.
The stock should stay supported by strong execution and diversified growth drivers, but VYKAT XR safety headlines may keep volatility elevated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings